Search Results

Andembry is the first monthly Factor XIIa inhibitor for the prevention of HAE attacks and will be available to patients “before the end of June,” CSL announced.

ABIONYX Pharma acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an acute myocardial infarction, did not meet its primary efficacy endpoint of MACE reduction at 90 days.

CSL Behring, a business unit of global biotechnology leader CSL, announced the availability of 4- and 5-gram vial sizes for ZEMAIRA®

CSL Behring today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid).